1] School of Biological Science, Nanyang Technological University, Singapore, Singapore [2] Pohang Center for Evaluation of Biomaterials, Pohang Technopark, Pohang, South Korea.
Exp Mol Med. 2013 Oct 11;45(10):e47. doi: 10.1038/emm.2013.91.
Here, we report that B-cell lymphoma 2 (Bcl-2) is a novel target molecule of aspirin in breast cancer cells. Aspirin influenced the formation of a complex by Bcl-2 and FKBP38 and induced the nuclear translocation of Bcl-2 and its phosphorylation. These events inhibited cancer cell proliferation and subsequently enhanced MCF-7 breast cancer cell apoptosis. Bcl-2 knockdown using small interfering RNA (siRNA) delayed apoptotic cell death, which correlated with increased proliferation following aspirin exposure. In contrast, Bcl-2 overexpression enhanced the onset of aspirin-induced apoptosis, which was also associated with a significant increase in Bcl-2 phosphorylation in the nucleus. Therefore, this study may provide novel insight into the molecular mechanism of aspirin, particularly its anticancer effects in Bcl-2- and estrogen receptor-positive breast cancer cells.
在这里,我们报告 B 细胞淋巴瘤 2(Bcl-2)是阿司匹林在乳腺癌细胞中的一个新的靶分子。阿司匹林影响 Bcl-2 和 FKBP38 形成复合物,并诱导 Bcl-2 的核转位及其磷酸化。这些事件抑制了癌细胞的增殖,并随后增强 MCF-7 乳腺癌细胞的凋亡。使用小干扰 RNA(siRNA)敲低 Bcl-2 延迟了凋亡细胞死亡,这与阿司匹林暴露后增殖增加相关。相比之下,Bcl-2 的过表达增强了阿司匹林诱导的凋亡的发生,这也与核内 Bcl-2 磷酸化的显著增加相关。因此,本研究可能为阿司匹林的分子机制,特别是其在 Bcl-2 和雌激素受体阳性乳腺癌细胞中的抗癌作用提供新的见解。